These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34140854)

  • 21. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.
    Pumpens P; Razanskas R; Pushko P; Renhof R; Gusars I; Skrastina D; Ose V; Borisova G; Sominskaya I; Petrovskis I; Jansons J; Sasnauskas K
    Intervirology; 2002; 45(1):24-32. PubMed ID: 11937768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system.
    Armero-Gimenez J; Wilbers R; Schots A; Williams C; Finnern R
    Front Immunol; 2023; 14():1088852. PubMed ID: 36776898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate.
    Lei Y; Shao J; Zhao F; Li Y; Lei C; Ma F; Chang H; Zhang Y
    J Med Virol; 2019 Dec; 91(12):2142-2152. PubMed ID: 31347713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.
    Schumacher J; Bacic T; Staritzbichler R; Daneschdar M; Klamp T; Arnold P; Jägle S; Türeci Ö; Markl J; Sahin U
    J Nanobiotechnology; 2018 Apr; 16(1):39. PubMed ID: 29653575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides.
    Petrovskis I; Skrastina D; Jansons J; Dislers A; Bogans J; Spunde K; Neprjakhina A; Zakova J; Zajakina A; Sominskaya I
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of the HBc Protein from Different HBV Genotypes in
    Petrovskis I; Lieknina I; Dislers A; Jansons J; Bogans J; Akopjana I; Zakova J; Sominskaya I
    Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
    Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
    Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
    Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
    PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography.
    Ladd Effio C; Oelmeier SA; Hubbuch J
    Vaccine; 2016 Mar; 34(10):1259-67. PubMed ID: 26845741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
    Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.
    Huang Z; Santi L; LePore K; Kilbourne J; Arntzen CJ; Mason HS
    Vaccine; 2006 Mar; 24(14):2506-13. PubMed ID: 16417953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling.
    Ji M; Zhu J; Xie XX; Liu DQ; Wang B; Yu Z; Liu RT
    Nanomedicine; 2020 Aug; 28():102223. PubMed ID: 32422220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles.
    Tang S; Xuan B; Ye X; Huang Z; Qian Z
    Sci Rep; 2016 May; 6():25741. PubMed ID: 27170066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.
    Moradi Vahdat M; Hemmati F; Ghorbani A; Rutkowska D; Afsharifar A; Eskandari MH; Rezaei N; Niazi A
    Biotechnol Rep (Amst); 2021 Mar; 29():e00605. PubMed ID: 33732633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
    Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
    Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus.
    Yang HJ; Chen M; Cheng T; He SZ; Li SW; Guan BQ; Zhu ZH; Gu Y; Zhang J; Xia NS
    World J Gastroenterol; 2005 Jan; 11(4):492-7. PubMed ID: 15641132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.
    Broos K; Janssens ME; De Goeyse I; Vanlandschoot P; Leroux-Roels G; Geysen D; Guisez Y
    Clin Vaccine Immunol; 2008 May; 15(5):852-8. PubMed ID: 18367580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.